Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs), announced the appointment of Dr. Ken Kramer, PhD, as senior vice president of medical affairs, effective immediately. Dr. Kramer brings more than two decades of neuroscience-focused medical affairs leadership, having held senior roles at Bristol Myers Squibb, Karuna Therapeutics, and AbbVie. His expertise is expected to support Helus Pharma in advancing its pipeline and strengthening engagement with clinical and scientific stakeholders.
Helus Pharma, the commercial operating name of Cybin Inc., is dedicated to developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. These investigational therapies aim to address the large unmet need for individuals suffering from depression, anxiety, and other mental health conditions. The company’s lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another proprietary NSA, is in Phase 2 trials for generalized anxiety disorder. Helus Pharma also maintains an extensive research portfolio of investigational NSAs.
Dr. Kramer’s appointment comes at a critical time as the company advances its clinical programs. His experience in medical affairs and neuroscience is expected to enhance Helus Pharma’s ability to communicate its scientific data and build relationships with key opinion leaders and regulatory bodies. The company operates in Canada, the United States, the United Kingdom, and Ireland, and is committed to improving the treatment landscape through durable improvements in mental health.
For more information on the appointment, visit the full press release at https://ibn.fm/FdEXH. Company updates and details about Helus Pharma are available at www.helus.com or by following the team on social media platforms such as X, LinkedIn, YouTube, and Instagram. Helus Pharma is a trademark of Cybin Corp.
This announcement underscores the company’s strategic focus on advancing its NSA pipeline, which holds promise for addressing major depressive disorder and generalized anxiety disorder—conditions with significant unmet medical needs. With Dr. Kramer’s leadership, Helus Pharma aims to strengthen its position in the neuroscience space and move closer to bringing innovative therapies to patients.
